Abstract
The present study was performed to investigate the enzyme inhibitory and antidiabetic activities of the constituents isolated from Callistemon lanceolatus. The leaves of C. lanceolatus were extracted with successively with petroleum ether, dichloromethane and methanol. The dried dichloromethane and methanol extracts were subjected to fractionation and chromatographic separation, which led to the isolation of seven compounds: 3-epi-betulinic acid (1), 3- epi-ursolic acid (2), oleanolic acid (3), ursolic acid (4), lup-12, 20(29)-diene-3α-ol-28-oic acid (5), heptacosenone (6) and kaempferol (7). Their structures were elucidated on the basis of spectroscopic studies as well as by comparison with the data available in the literature. Among these isolates, compounds 1, 2, 3, 4 and 7 were evaluated for in vitro enzyme inhibition effect. Compounds 1, 2, 3, 4 and 7 showed 38.34, 52.59, 62.4, 54.95 and 32.43 % α-amylase inhibition respectively and 49.27, 53.34, 84.2, 67.98 and 52.25 % α-glucosidase inhibition respectively at the concentration of 50 µg/kg. Compounds 3, 4 and 7 were also showed antidiabetic activity in streptozotocin-nicotinamide induced diabetic mice at the dose of 10 mg/kg.
Keywords: α-amylase inhibition, antidiabetic, Callistemon lanceolatus, α-glucosidase inhibition, streptozotocin-nicotinamide, ursolic acid.
The Natural Products Journal
Title:Enzymes Inhibition and Antidiabetic Effect of Isolated Constituents from Callistemon lanceoalatus
Volume: 3 Issue: 4
Author(s): Sunil Kumar, Vipin Kumar, Om Prakash and Mohammed Ali
Affiliation:
Keywords: α-amylase inhibition, antidiabetic, Callistemon lanceolatus, α-glucosidase inhibition, streptozotocin-nicotinamide, ursolic acid.
Abstract: The present study was performed to investigate the enzyme inhibitory and antidiabetic activities of the constituents isolated from Callistemon lanceolatus. The leaves of C. lanceolatus were extracted with successively with petroleum ether, dichloromethane and methanol. The dried dichloromethane and methanol extracts were subjected to fractionation and chromatographic separation, which led to the isolation of seven compounds: 3-epi-betulinic acid (1), 3- epi-ursolic acid (2), oleanolic acid (3), ursolic acid (4), lup-12, 20(29)-diene-3α-ol-28-oic acid (5), heptacosenone (6) and kaempferol (7). Their structures were elucidated on the basis of spectroscopic studies as well as by comparison with the data available in the literature. Among these isolates, compounds 1, 2, 3, 4 and 7 were evaluated for in vitro enzyme inhibition effect. Compounds 1, 2, 3, 4 and 7 showed 38.34, 52.59, 62.4, 54.95 and 32.43 % α-amylase inhibition respectively and 49.27, 53.34, 84.2, 67.98 and 52.25 % α-glucosidase inhibition respectively at the concentration of 50 µg/kg. Compounds 3, 4 and 7 were also showed antidiabetic activity in streptozotocin-nicotinamide induced diabetic mice at the dose of 10 mg/kg.
Export Options
About this article
Cite this article as:
Kumar Sunil, Kumar Vipin, Prakash Om and Ali Mohammed, Enzymes Inhibition and Antidiabetic Effect of Isolated Constituents from Callistemon lanceoalatus, The Natural Products Journal 2013; 3 (4) . https://dx.doi.org/10.2174/221031550304140328112456
DOI https://dx.doi.org/10.2174/221031550304140328112456 |
Print ISSN 2210-3155 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-3163 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Invasive Markers of Liver Fibrosis in HCV Mono-Infected and in HIV/HCV Co-Infected Subjects
Medicinal Chemistry Recent Patents on Whey Protein Hydrolysates Manufactured by Proteolysis Coupled to Membrane Ultrafiltration
Recent Patents on Chemical Engineering Traditional Chinese Medicine in Treatment of Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews The Role of Intracellular 35-Cyclic Adenosine Monophosphate (cAMP) in Atherosclerosis
Current Vascular Pharmacology MDMA Administration and Heat Shock Proteins Response: Foreseeing a Molecular Link
Current Pharmaceutical Biotechnology Pharmacogenomics and Sepsis-Induced Renal Failure: Effects of β 2-Adrenoceptor Function on the Course of Sepsis
Current Pharmacogenomics and Personalized Medicine Indazole Derivatives: Promising Anti-tumor Agents
Anti-Cancer Agents in Medicinal Chemistry Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer’s Disease
Current Aging Science Cardiovascular Complications in Patients with Turner’s Syndrome
Current Pharmaceutical Design MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers High Fat Meal Increase of IL-17 is Prevented by Ingestion of Fruit Juice Drink in Healthy Overweight Subjects
Current Pharmaceutical Design Interaction Between Platelets and Cytokines - A Possible Role in the Pathogenesis of Preeclampsia
Vascular Disease Prevention (Discontinued) Do Rheumatoid Arthritis Patients Rate their Health Status Different than their Caregivers?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Retracted: Tocotrienols and its Role in Cardiovascular Health- a Lead for Drug Design
Current Pharmaceutical Design The Role of Colchicine in the Prevention of Cerebrovascular Ischemia
Current Pharmaceutical Design The Many Roles of Statins in Ischemic Stroke
Current Neuropharmacology Peripheral Arterial Disease and Oxidative Stress
Vascular Disease Prevention (Discontinued)